H. J. Zeiler – författare
Visar alla böcker från författaren H. J. Zeiler. Handla med fri frakt och snabb leverans.
3 produkter
3 produkter
Perspectives in Antiinfective Therapy
Bayer AG Centenary Symposium Washington, D. C., Aug. 31–Sept. 3, 1988
Häftad, Tyska, 1989
576 kr
Skickas inom 10-15 vardagar
1 114 kr
Skickas inom 10-15 vardagar
At a symposium in Wuppertal held on 26 September 1995, Dr. Karl-Georg Metzger was honored, on the occasion of his retirement, for his scientific contributions and involvement in antibacterial drug research and develop ment within Bayer AG. In 1963 Dr. Metzger was the first "molecular micro biologist" to join Bayer in the field of antibacterial research. Karl-Georg Metzger studied physics and biology at the University of Mainz from 1950 to 1953 and continued his scientific education, with a grant from the Deutsche Forschungsgemeinschaft, in Frankfurt on Main (1953-1956). From 1956 to 1958, under Professor Kaplan, he worked on his DNA following treatment of PhD, studying on "Energy conduction along bacteria with UV light and X-rays and the formation of mutations". He was awarded his PhD in 1959. From 1958 to 1963 he was research assistant in ra diobiology development at the Institute of Genetics in Cologne. During the following years he became fascinated by the emerging fields of molecular biology and gene technology. He worked together with the molecular gen eticists W. Harms and M. Delbriick, who built up one of the most renowned institutes in the world, in Cologne. ''An incredibly interesting time:' Dr. Metzger remembers, in which he got to know a whole series of Nobel prize winners from Niels Bohr to Watson and Crick and Joshua Lederberg, the first to recombine genotypes of bacteria.
1 114 kr
Skickas inom 10-15 vardagar
It has been over 30 years since the first clinically important member of the quinolone class, nalidixic acid, was introduced into medical practice. The modification produced in the quinolone nucleus by introducing a fluorine at the 6-position led to the discovery of the newer fluoroquinolones with enhanced antibacterial activities as compared to nalidixic acid. By now a great deal of preclinical and clinical experience has been obtained with these agents. The intense interest in this class of antibacterial agents by chemists, micro biologists, toxicologists, pharmacologists, clinical pharmacologists, and clini cians in various disciplines encouraged us to summarize the information on the history, chemistry, mode of action and in vitro properties, kinetics and efficacy in animals, mechanisms of resistance, toxicity, clinical pharmacology, clinical experience, and future prospects in one volume of the Handbook of Experimental Pharmacology. As this series deals predominantly with "experimental" characteristics of drugs, our volume is dedicated specifically to quinolones and emphasizes principally their preclinical and clinical phar macological characteristics, despite the existence of several summaries on quinolones. The chemistry of the quinolones is described in detail. The chapter on the mode of action of quinolones reports the conclusive evidence that gyrase is the intracellular target of the quinolones; however, another enzyme, topoisomerase IV, may also be a target for quinolones, and the exact mechanisms by which quinolones act bactericidally are far from being understood.